Two features of this transport process remain incompletely understood, however. First, mutations in SLC19A3 cause a progressive disorder that is responsive to biotin treatment (Zhou et al. 2005), although studies of cultured cells indicate that the protein has no affinity for biotin (Subramanian et al. 2006 - Am J Physiol). Also, studies to date provide little information about the mechanism by which thiamin, once taken up by epithelial cells in the intestine and kidney, is released from these cells into the blood.
Said, HM, Ashokkumar, B, Vaziri, ND
Said, HM, Subramanian, VS, Marchant, JS, Balamurugan, K
Said, HM, Subramanian, VS, Marchant, JS
Cohen, N, Tartaglini, E, Fleming, JC, Schorderet, DF, Steinkamp, MP, Neufeld, EJ
Banikazemi, M, Oishi, K, Gelb, BD, Diaz, GA, Desnick, RJ
Cohen, N, Nosaka, K, Williams, H, Mandel, H, Gregory, S, McDonald, L, Baron, D, Labay, V, Szargel, R, Barrett, T, Shalata, A, Raz, T
thiamine transmembrane transporter activity of SLC19A2/3 [plasma membrane]
© 2025 Reactome